 |
|
|
| |
Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in Hispanic/Latinx and Black Participants:
Efficacy, Bone and Renal Safety Results From a Pooled Analysis of 7 Clinical Trials
|
| |
| |
Reported by Jules Levin
IDWeek 2019™, October 2-6, 2019, Washington, DC
Edwin DeJesus,1 Jaime Federico Andrade Villanueva,2 Jose Ramon Arribas Lopez,3 Cynthia Brinson,4 Gordon Crofoot,5 Eric S. Daar,6 Ellen Koenig,7 Daniel Podzamczer,8 Moti N. Ramgopal,9
Jorge L. Santana-Bagur,10 Lizette Santiago,11 Pablo Tebas,12 Carmen Zorrilla,13 Susan Guo,14 Ya-Pei Liu,14 Lijie Zhong,14 Diana M. Brainard,14 Christoph Carter,14 Lauren Temme,14 Moupali Das14
1Orlando Immunology Center, Orlando, FL; 2Hospital Civil de Guadalajara, Mexico; 3Hospital Universitario La Paz, Madrid, Spain; 4Central Texas Clinical Research, Austin, TX; 5Gordon E. Crofoot MD, PA, Houston, TX; 6Los Angeles Biomedical Research Institute, Torrance, CA; 7Instituto Dominicano de Estudios Virologicos, Santo Domingo, Republica Dominicana; 8Hospital Universitari de Bellvitge, Barcelona, Spain; 9Midway Research Center, Fort Pierce, FL; 10La Escuela de Medicina del Recinto de Ciencias Medicas de la Universidad de Puerto Rico, San Juan; 11Hope Clinical Research, San Juan; 12University of Pennsylvania, Philadelphia; 13Maternal Infant Study Center, La Escuela de Medicina del Recinto de Ciencias Medicas de la Universidad de Puerto Rico; 14Gilead Sciences, Inc., Foster City, CA
|
| |
|
|
|
|
|
